title: Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.
abstract: BACKGROUND
  The level of platelet inhibition by a Glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist therapy necessary to minimize thrombotic complications in patients undergoing percutaneous coronary intervention (PCI) is a subject of debate. The degree of platelet inhibition obtained 10 min after start of GpIIb/IIIa antagonist therapy predicts adverse events after PCI. The aim of this study was to look at platelet inhibition and to compare platelet GpIIb/IIIa receptors occupancy ratio (GpRO) with Eptifibatide and Tirofiban using various dose regimens and correlate with 30-day clinical outcomes in patients presenting with high-risk acute coronary syndromes (ACS) and undergoing PCI.
  
  
  METHODS
  The patients were divided into four sub groups: (1) Eptifibatide two intracoronary bolus (180 μg/kg) alone (E(B)); or (2) two intravenous bolus (180 μg/kg) followed by infusion at 2 μg/kg/min for 24 h (E(B + Inf)); and (3) Tirofiban standard bolus dose (0.4 μg/kg) over 30 min followed by infusion at 0.1 μg/kg/min (T(Std)); or (4) at ADVANCE dose bolus (25 μg/kg) over 3 min, followed by infusion at 0.1 μg/kg/min (T(Adv)). Number of GpIIb/IIIa receptors was assessed by flow cytometry at baseline and 10 min after the bolus and percentage of free receptors was determined to calculate the GpRO. Patients were followed for 30 days for any major adverse cardiac events (MACE).
  
  
  RESULTS
  200 consecutive patients (including 74% with ST-elevation ACS) were enrolled. GpRO in groups E(B) (n = 48) and E(B + Inf) (n = 44) were 62.7% ± 27.2% and 61.4% ± 6.1% respectively while in the groups T(Std) (n = 96) and T(Adv) (n = 12) groups were 35.1% ± 17.74% and 68.8% ± 27.3% respectively. The GpRO was similar in E(B), E(B + Inf) and T(Adv) groups and was significantly higher than T(Std) group (p < 0.0001). The 30-day MACE rates in E(B) (4.2%), E(B + Inf) (4.5%) and T(Adv) (4.2%) were significantly lower than T(Std) group (12.5%) (p < 0.01).
  
  
  CONCLUSIONS
  Standard dose Tirofiban results in significantly lower rates of GpIIb/IIIa receptor occupancy ratio and this correlated with higher incidence of 30-day MACE in high-risk ACS patients undergoing PCI.
authors: Associate Professor, Department of Cardiology, CSM Medical University (Erst. King George Medical University), B-58 Sector A, Mahanagar, Lucknow, India. Electronic address: aniketpuri@hotmail.com.
authors: Aniket
authors: A
authors: Puri
authors: A
authors: A
authors: Bansal
authors: V S
authors: VS
authors: Narain
authors: R
authors: R
authors: Sethi
authors: S K
authors: SK
authors: Dwivedi
authors: V K
authors: VK
authors: Puri
authors: R K
authors: RK
authors: Saran
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D001792:Blood Platelets / Q000187:drug effects*; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors / Q000187:drug effects*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide
references: Circulation. 2010 Feb 16;121(6):784-91
references: 20124127
references: Circulation. 1994 Oct;90(4):1757-64
references: 7923659
references: Am Heart J. 2006 Nov;152(5):812-4
references: 17070138
references: Circulation. 1993 Jul;88(1):37-42
references: 7686453
references: Circulation. 2001 May 29;103(21):2572-8
references: 11382726
references: Catheter Cardiovasc Interv. 2001 Dec;54(4):497-504
references: 11747189
references: Lancet. 1997 May 17;349(9063):1422-8
references: 9164315
references: J Am Coll Cardiol. 2004 Jul 7;44(1):14-9
references: 15234398
references: J Am Coll Cardiol. 2000 Apr;35(5):1103-15
references: 10758948
references: Blood. 1996 Jun 15;87(12):4925-36
references: 8652804